Gold gem, AI fantasy, and pharmaceutical giant! Which stock will take off in 2026? TeamViewer, Novo Nordisk, Laurion Mineral Exploration

LAURION Mineral Exploration: Gold gem with price potential

In the gold sector, the run on second-tier latecomers is likely to start in 2026, as the major producers such as Barrick Mining and Newmont have already performed very well. In addition, with the gold price at record levels, the takeover merry-go-round is also likely to spin faster. LAURION Mineral Exploration stands to benefit from both trends. In recent years, the Company has focused on exploration and has done little in the way of capital market communication. It is only since the fall of 2025 that management has been putting the Company on investors' radar with active communication.

In December, LAURION CEO Cynthia Le Sueur-Aquin presented at the IIF virtual investor conference. She presented the Ishkōday project as the Company's flagship property. It is located in the Greenstone District in northern Ontario and currently comprises a contiguous concession package of approximately 57 sq km. In her view, the combination of a "Tier 1" jurisdiction and operational feasibility is crucial: exploration permits were granted at an early stage, and access is possible all year round. In addition, there is electricity and water supply as well as a regional workforce. Le Sueur-Aquin also emphasized the cooperation with three First Nations, with whom exploration agreements have already been concluded – a point that is relevant for further project development and, in particular, for later operating agreements.

Geologically, LAURION positions Ishkōday in a structurally defined system along regional fault zones that have historically enabled gold production. Several million ounces of gold were produced in the region up to the late 1960s, alongside silver, zinc, copper, and lead. She cited the historic Sturgeon River mine as a reference, among others.

Operationally, LAURION is currently focusing on a six-kilometer-long corridor, where various zones are to be gradually connected and better delineated. High-grade drill results had already been reported in October. Samples yielded 32.47 g/t gold and 67.80 g/t gold. Management sees the historic tailings around the Sturgeon River mine as a key short-term value driver. Based on earlier surveys and subsequent investigations, LAURION estimates the size of the tailings to be around 190,000 tons of material. Subject to approval, these stocks could represent an option for early processing. At the same time, exploration in the core area is to be further intensified in 2026. More targeted drilling in the higher-grade orogenic structures (Sturgeon River) and near-surface extension drilling are to form the basis for an initial resource estimate. On the financial side, the CEO outlined a shareholder structure heavily influenced by insiders (around three-quarters insiders/friends/family) and what she considers to be a disciplined cost base with a low burn rate.

Novo Nordisk: Starting the new year with momentum

Novo Nordisk shareholders had little to cheer about in 2025. Only thanks to a small year-end rally did the share price not plummet by more than 50%. The share is currently trading at around EUR 45. In June 2024, it was trading at over EUR 130. This means that the share price has fallen back to its 2022 level and has lost all the gains made during the Ozempic hype. High internal costs, disappointing study results, management changes, and reduced forecasts caused great disappointment for the pharmaceutical company, which is accustomed to success.

At least the Company is entering the new year with momentum.
Shortly before Christmas, the US Food and Drug Administration (FDA) approved the Wegovy tablet for reducing obesity. Novo Nordisk expects to launch the Wegovy pill in the US in early January 2026. The application for approval is still being processed by the European Medicines Agency (EMA).

In its press release, Novo Nordisk emphasized that the Wegovy tablet is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight loss. In the OASIS study, which was important for approval, once-daily administration of 25 mg of oral semaglutide resulted in an average weight loss of 16.6% when treatment was adhered to in adult participants with obesity or overweight. In addition, one in three study participants achieved a weight loss of 20% or more. This means that the weight loss achieved with the pill was on par with that achieved with the injection.

TeamViewer: AI fantasy is not enough

TeamViewer shares ended 2025 at virtually their lowest level of the year. Since reaching an annual high of EUR 13 in April, the stock has more than halved in value and is now trading below EUR 6. The share price has lost around 40% over the year. It has been falling steadily since the profit warning in May. The exit of major shareholder Permira also weighed on the stock.

However, analysts now see potential for the share price to rise. According to marketscreener.com, the average target price set by experts is EUR 10.48. However, there have been some critical voices recently. JPMorgan emphasized that TeamViewer had recently disappointed in terms of growth and lost confidence. They therefore rate the German software specialist's shares as "Neutral." Analysts see the fair value at EUR 7.50.

Even with AI fantasy, the Company is currently unable to inspire investors. In November, TeamViewer reported growing interest in its AI solutions. Many IT teams reported noticeable efficiency gains. Tickets could be resolved up to 25% faster. Documentation would take about ten minutes less per case on average. As a result, usage figures had risen significantly three months after the global launch. Around 10,000 customers had already activated the AI functions. From August to October, the volume had quadrupled compared to the previous three months.

Concrete figures are needed to build confidence among shareholders. The figures for the fourth quarter and full year 2025 are to be published on February 10, 2026.

LAURION Mineral Exploration is a hidden gem among gold explorers – for now. The project looks promising, and management is taking a very serious approach. With good news flow, the stock is unlikely to remain cheap for long. Novo Nordisk also appears to have bottomed out. However, it needs more than just the weight loss pill. Meanwhile, buying TeamViewer shares is not an obvious choice at the moment.